Kwak N, Kim H-R, Yoo C-G, Kim Y W, Han S K, Yim J-J
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Science, Seoul, Republic of Korea.
Int J Tuberc Lung Dis. 2015 May;19(5):525-30. doi: 10.5588/ijtld.14.0739.
After several changes in treatment modalities, it is time to re-evaluate treatment outcomes of multidrug-resistant tuberculosis (MDR-TB).
To evaluate treatment outcomes, elucidate changes in outcomes over time and identify predictors of treatment success for MDR-TB.
Patients diagnosed with MDR-TB at a tertiary referral centre in South Korea between January 2006 and December 2010 were included. Treatment modalities and outcomes were assessed. Predictors of treatment success were analysed using multiple logistic regression. The treatment modalities and outcomes of these patients were compared with those of MDR-TB patients between January 1996 and December 2005.
Of the 123 MDR-TB patients diagnosed during the later study period, treatment was successful in 103 (83.7%). Extensive drug resistance (OR 0.31, P = 0.044) and additional resistance to fluoroquinolones (OR 0.23, P = 0.039) were inversely associated with treatment success. The treatment success rate improved from 53.5% in 1996-2000 to 68.8% in 2001-2005 and 83.7% in 2006-2010 (P < 0.001). Improved outcomes were accompanied with more frequent use of later-generation fluoroquinolones and linezolid and less frequent surgical resection.
Treatment outcomes for MDR-TB improved at a tertiary referral centre in South Korea. The improvement was associated with more frequent use of later-generation fluoroquinolones and linezolid.
在治疗方式经过多次改变后,是时候重新评估耐多药结核病(MDR-TB)的治疗效果了。
评估治疗效果,阐明治疗效果随时间的变化,并确定耐多药结核病治疗成功的预测因素。
纳入2006年1月至2010年12月在韩国一家三级转诊中心被诊断为耐多药结核病的患者。评估治疗方式和效果。使用多元逻辑回归分析治疗成功的预测因素。将这些患者的治疗方式和效果与1996年1月至2005年12月期间的耐多药结核病患者进行比较。
在后期研究期间诊断的123例耐多药结核病患者中,103例(83.7%)治疗成功。广泛耐药(比值比0.31,P = 0.044)和对氟喹诺酮类药物的额外耐药(比值比0.23,P = 0.039)与治疗成功呈负相关。治疗成功率从1996 - 2000年的53.5%提高到2001 - 2005年的68.8%,以及2006 - 2010年的83.7%(P < 0.001)。治疗效果的改善伴随着更频繁地使用新一代氟喹诺酮类药物和利奈唑胺,以及手术切除频率的降低。
韩国一家三级转诊中心耐多药结核病的治疗效果有所改善。这种改善与更频繁地使用新一代氟喹诺酮类药物和利奈唑胺有关。